235 related articles for article (PubMed ID: 16890938)
21. [Steroid treatment in four cases of anti-GAD cerebellar ataxia].
Bonnan M; Cabre P; Olindo S; Signate A; Saint-Vil M; Smadja D
Rev Neurol (Paris); 2008 May; 164(5):427-33. PubMed ID: 18555874
[TBL] [Abstract][Full Text] [Related]
22. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity.
Gresa-Arribas N; Ariño H; Martínez-Hernández E; Petit-Pedrol M; Sabater L; Saiz A; Dalmau J; Graus F
PLoS One; 2015; 10(3):e0121364. PubMed ID: 25774787
[TBL] [Abstract][Full Text] [Related]
23. GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders.
Fouka P; Alexopoulos H; Akrivou S; Trohatou O; Politis PK; Dalakas MC
J Neuroimmunol; 2015 Apr; 281():73-7. PubMed ID: 25867471
[TBL] [Abstract][Full Text] [Related]
24. Glutamate alteration of glutamic acid decarboxylase (GAD) in GABAergic neurons: the role of cysteine proteases.
Monnerie H; Le Roux PD
Exp Neurol; 2008 Sep; 213(1):145-53. PubMed ID: 18599042
[TBL] [Abstract][Full Text] [Related]
25. [Autoantibodies to GAD and autoimmune-mediated neurological diseases].
Mitoma H; Mizusawa H
Nihon Rinsho; 2013 May; 71(5):921-6. PubMed ID: 23777105
[TBL] [Abstract][Full Text] [Related]
26. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy.
Peltola J; Kulmala P; Isojärvi J; Saiz A; Latvala K; Palmio J; Savola K; Knip M; Keränen T; Graus F
Neurology; 2000 Jul; 55(1):46-50. PubMed ID: 10891904
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic plasma exchange and immunosuppressive therapy in a patient with anti-GAD antibody-related epilepsy: quantification of the antibody response.
Farooqi MS; Lai Y; Lancaster E; Schmitt SE; Sachais BS
J Clin Apher; 2015 Feb; 30(1):8-14. PubMed ID: 24961613
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the GAD65-GAD65 autoantibody interaction.
Coco G; Chen S; Powell M; Brooking H; Zanchetta R; Betterle C; Smith BR; Furmaniak J
Clin Chim Acta; 2008 May; 391(1-2):51-9. PubMed ID: 18328264
[TBL] [Abstract][Full Text] [Related]
29. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome.
Butler MH; Solimena M; Dirkx R; Hayday A; De Camilli P
J Exp Med; 1993 Dec; 178(6):2097-106. PubMed ID: 8245784
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies.
Falip M; Carreño M; Miró J; Saiz A; Villanueva V; Quílez A; Molins A; Barceló I; Sierra A; Graus F
Eur J Neurol; 2012 Jun; 19(6):827-33. PubMed ID: 22353320
[TBL] [Abstract][Full Text] [Related]
31. Spontaneous downbeat nystagmus as a clue for the diagnosis of ataxia associated with anti-GAD antibodies.
Vale TC; Pedroso JL; Alquéres RA; Dutra LA; Barsottini OG
J Neurol Sci; 2015 Dec; 359(1-2):21-3. PubMed ID: 26671081
[TBL] [Abstract][Full Text] [Related]
32. Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study.
Kwan P; Sills GJ; Kelly K; Butler E; Brodie MJ
Epilepsy Res; 2000 Dec; 42(2-3):191-5. PubMed ID: 11074191
[TBL] [Abstract][Full Text] [Related]
33. Anti-GAD antibodies and periodic alternating nystagmus.
Tilikete C; Vighetto A; Trouillas P; Honnorat J
Arch Neurol; 2005 Aug; 62(8):1300-3. PubMed ID: 16087772
[TBL] [Abstract][Full Text] [Related]
34. Apraxia in anti-glutamic acid decarboxylase-associated stiff person syndrome: link to corticobasal degeneration?
Bowen LN; Subramony SH; Heilman KM
Ann Neurol; 2015 Jan; 77(1):173-6. PubMed ID: 25100431
[TBL] [Abstract][Full Text] [Related]
35. Non-convulsive status epilepticus associated with glutamic acid decarboxylase antibody.
Cikrikçili U; Ulusoy C; Turan S; Yildiz S; Bilgiç B; Hanagasi H; Baykan B; Tüzün E; Gürvit H
Clin EEG Neurosci; 2013 Jul; 44(3):232-6. PubMed ID: 23820312
[TBL] [Abstract][Full Text] [Related]
36. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies.
Dalakas MC; Li M; Fujii M; Jacobowitz DM
Neurology; 2001 Sep; 57(5):780-4. PubMed ID: 11552003
[TBL] [Abstract][Full Text] [Related]
37. Reversibility of cerebellar GABAergic synapse impairment induced by anti-glutamic acid decarboxylase autoantibodies.
Ishida K; Mitoma H; Mizusawa H
J Neurol Sci; 2008 Aug; 271(1-2):186-90. PubMed ID: 18534624
[TBL] [Abstract][Full Text] [Related]
38. Effects of antisense glutamic acid decarboxylase oligodeoxynucleotide on epileptic rats induced by pentylenetetrazol.
He X; Wang W; Ruan X; Li W; Zhang L
Chin Med J (Engl); 2002 Mar; 115(3):425-9. PubMed ID: 11940381
[TBL] [Abstract][Full Text] [Related]
39. Clinical spectrum of glutamic acid decarboxylase antibodies in a Taiwanese population.
Kuo YC; Lin CH
Eur J Neurol; 2019 Nov; 26(11):1384-1390. PubMed ID: 31132202
[TBL] [Abstract][Full Text] [Related]
40. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase.
Ishida K; Mitoma H; Song SY; Uchihara T; Inaba A; Eguchi S; Kobayashi T; Mizusawa H
Ann Neurol; 1999 Aug; 46(2):263-7. PubMed ID: 10443895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
